Two varieties of chrysanthemum have similar therapeutic effects but operate through distinct mechanisms, revealing potential for precise applications in both traditional and modern medicine.
The study combined network pharmacology, molecular pharmacology, and metabolomics to clarify differences between two herbs, CMF and CIF. An initial analysis was carried out via HPLC-Q-TOF-MS which revealed distinct flavonoid constituents between CMF and CIF. These findings led researchers to make predictions about the possible biological processes responsible for the therapeutic effects of these herbs on LFHSH, including their influence on inflammatory response and fatty acid production.
Through a series of ELISA, molecular docking, Western blot, and metabolomics techniques, the research identified similar influences of CMF and CIF on blood pressure and resistance to tissue, organ and functional damage as well as dyslipidemia. Despite the similar outcomes, there was variation in their mechanism of action. Namely, these herbs uniquely influenced inflammatory response, various signaling pathways, lipid anabolism, the renin-angiotensin system, and metabolic abnormalities. Differing effects were believed to be due to each herb's unique regulatory capabilities which, despite the end effect similarities, offer unique pathways for effective medical application.
